Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Annual revenue, net income & balance sheet · SEC EDGAR XBRL data
Revenue (2024)
$9.1M
Net Income (2024)
$209K
YoY Revenue
+16.6%
Total Assets (2024)
$5.2M
Financial Intelligence · Sprytne.com
International Stem Cell CORP (ISCO) reported $9.1M in revenue for fiscal year 2024. The company posted a net loss of $209K. Year-over-year revenue growth: +16.6%. Total assets: $5.2M.
Source: SEC EDGAR XBRL — Standardized Financial Data · CIK 0001355790
| Year | Revenue | Net Income |
|---|---|---|
| 2024(latest) | $9.1M | ($209K) |
| 2023 | $7.8M | ($131K) |
| 2022 | $8.2M | ($331K) |
| 2021 | $7.2M | ($899K) |
| 2020 | $7.1M | ($2.7M) |
| Item | Amount |
|---|---|
| Total Assets | $5.2M |
| Current Assets | $3.6M |
| Total Liabilities | $4.8M |
| Current Liabilities | $4.7M |
| Stockholders' Equity | ($3.9M) |
International Stem Cell CORP reported $9.1M in revenue for fiscal year 2024, according to SEC EDGAR XBRL filings.
International Stem Cell CORP reported a net loss of $209K in 2024.
International Stem Cell CORP had total assets of $5.2M as of fiscal year 2024, per SEC EDGAR filings.
Company Profile
International Stem Cell CORP
SEC filings, executives & overview
Federal Contracts
International Stem Cell CORP
USASpending.gov award data
All Financials
Company Financial Database
6,800+ SEC-reported companies
Source: SEC EDGAR XBRL — CIK 0001355790. Annual financial data from 10-K filings. Values in USD. Fiscal years may differ from calendar years. Data fetched Mar 2026.